Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Next Previous
Trial Profile

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRTX 1719 (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Mesothelioma; Nerve sheath neoplasms; Non-small cell lung cancer; Pancreatic cancer; Peripheral nervous system neoplasms; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Bristol-Myers Squibb; Mirati Therapeutics

Most Recent Events

  • 06 May 2025 Phase of the study is changed from Phase 1/2 to phase 1. Patient number is accordingly decreased. Number of treatment arms are also decreased from 3 to 2 by the removal of Experimental: Phase 2 arm.
  • 06 May 2025 Phase of the study is changed from Phase 1/2 to phase 1. Patient number is accordingly decreased. Number of treatment arms are also decreased from 3 to 2 by the removal of Experimental: Phase 2 arm.
  • 06 May 2025 Planned number of patients changed from 580 to 320.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top